Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic dysfunction-associated steatotic liver disease, or MASLD.
The company said its 18-minute Elecsys PRO-C3 blood test, run on its cobas e instruments, is used alongside a formula that accounts for other clinical information—such as the patient’s age, diabetes status and platelet count. Its findings can help guide treatment and potentially provide access to upcoming therapies.